Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction.

ABSTRACT:

Lessons learned

Intravenous paricalcitol did not improve the efficacy of pembrolizumab, likely related to the short half-life.

Background

Immunotherapy has limited benefit in the treatment of advanced pancreatic cancer with the tumor microenvironment playing a key role in immune resistance. In preclinical studies, vitamin D receptor (VDR) agonists have been shown to sensitize pancreatic tumors to PD-1 blockade.

Methods

This was a randomized, double-blinded, placebo-controlled, phase II trial to evaluate pembrolizumab with or without paricalcitol as maintenance therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Participants were ≥18 years; histologically or cytologically confirmed metastatic PDAC showing no disease progression after frontline

SUBMITTER: Chung V 

PROVIDER: S-EPMC11756276 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature